Predicting lung cancer return after surgery
Part of Cancer, Lungs & breathing clinical trials.
This study tests a new way to predict if non-small cell lung cancer will return after surgery. You will give blood samples to look for cancer cells, and the team will build a model to help plan better follow-up care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You had non-small cell lung cancer that could be removed with surgery (early stage 1a to 3a).
- Your tumor was removed during surgery.
- After surgery, your cancer stage was between 1a1 and 3a (not stage 3b or 4).
- You finished your planned cancer treatment (like chemotherapy or radiation).
- You can give blood samples for special tests and go to checkups.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial looks at information and tissue from people with stage I to stage IIIA non-small cell lung cancer (NSCLC) who have surgery, sometimes with chemotherapy before surgery. Researchers want to understand why cancers come back (resistance) and how to better target treatments later.
This study checks whether a special blood test (ctDNA) taken before and after surgery can predict whether non-small cell lung cancer will come back. If it works, it may help doctors spot recurrence earlier and guide follow-up care after tumor removal.
This study looks at tiny particles from the body (including from lung samples) to see if they can predict whether non-small cell lung cancer comes back after surgery. It may help doctors identify people at higher risk of recurrence sooner, so follow-up plans can be better tailored.
This study looks at whether checking for tiny traces of cancer left in the blood (called minimal residual disease) after treatment can tell if lung cancer might come back. It may help doctors decide how often to monitor patients in the future.
This Phase 1 trial tests whether giving chemotherapy along with surgery is safe and tolerable for people with recurrent non-small cell lung cancer. It may help guide future treatment for cancer that has returned, especially if it has not spread to distant sites.
This trial uses a blood test to look for tiny bits of cancer DNA after treatment. It may help find early signs that lung cancer has come back, so doctors can act sooner.
Hear when a new Lung cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.